KELLIE DUARTE: Open Payments
NPI 1306034277 · KENNEWICK, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,260 in 182 payments from 19 companies in 2025. Trend: 2023 $2,517 · 2024 $3,051 · 2025 $3,260
Food & beverage: $3,004Education: $256
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 52 | $691 |
| ABBVIE INC. | 53 | $606 |
| UCB, Inc. | 19 | $438 |
| GENZYME CORPORATION | 9 | $279 |
| Galderma Laboratories, L.P. | 5 | $211 |
| Incyte Corporation | 7 | $178 |
| Regeneron Healthcare Solutions, Inc. | 5 | $159 |
| Lilly USA, LLC | 6 | $120 |
| Blueprint Medicines Corporation | 1 | $118 |
| BioWound Solutions, Inc. | 7 | $96 |
Products named: TREMFYA, Bimzelx, DUPIXENT, RINVOQ, SKYRIZI, NEMLUVIO, OPZELURA, AYVAKIT.
Industry payments across WA — which companies pay providers there.
